Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
Clinical trial NCT05243641 · TERMINATED
Trial details
- NCT number
- NCT05243641
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-18
- Primary completion
- 2024-11-19
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.